Pharmacological treatment of psychosis in epilepsy;Tratamento farmacológico das psicoses na epilepsia

Revista Brasileira de Psiquiatria

Volumn 26, Issue 1, 2004, Pages 57-61

  Guarnieri, Ricardo ^a   Cecílio Hallak, Jaime Eduardo ^b   Walz, Roger ^a   Rodrigues Velasco, Tonicarlo ^a   Alexandre Jr , Veriano ^a   Terra Bustamante, Vera Cristina ^a   Wichert Ana, Lauro ^a   Sakamoto, Américo Ceiki ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antipsychotic agents; Epilepsy; Psychotic disorder; Therapeutics

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROIC ACID; VIGABATRIN;

COMORBIDITY; CONVULSION; DISABILITY; DOSE RESPONSE; DRUG METABOLISM; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; PSYCHOSIS; PSYCHOSIS OF EPILEPSY; REVIEW; SEIZURE; SEIZURE THRESHOLD;

EID: 1842529046     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462004000100014     Document Type: Review

References (40)

1. Hauser WA. Incidence and prevalence. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven Publishers; 1997. p. 47-57.
2. Bettis TA. Depression, anxiety and epilepsy. In: Reynolds EH, Trimble MR, eds. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone; 1981. p. 61-71.
3. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999;40(Suppl 10):S2-S20.
4. Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998;155(3):325-36.
5. Lambert MV, David AS. Psychiatric comorbidity. In: Intractable focal epilepsy. Oxbury JM, Charles E Polkey, Michael Duchowny, eds. Toronto: WB Saunders; 2000. p. 445-71.
6. Scholtes FB, Renier WO, Meinardi H. Non-convulsive status epilepticus: causes, treatment, and outcome in 65 patients. J Neurol Neurosurg Psychiatry 1996;61(1):93-5.
7. Kanner AM, Barry JJ. Is the psychopathology of epilepsy different from that of nonepileptics patients? Epilepsy & Behavior 2001;2:170-86.
8. Williamson PD, Spencer SS. Clinical and EEG features of complex partial seizures of extratemporal origin. Epilepsia 1986;27(Suppl 2):S46-S63.
9. Kanner AM, Stagno S, Kotagal P, Morris HH. Postictal psychiatric events during prolonged video-electroencephalographic monitoring studies. Arch Neurol 1996;53(3):258-63.
10. Lancman ME, Craven WJ, Asconape JJ, Penry JK. Clinical management of recurrent postictal psychosis. J Epilepsy 1994;7:47-51.
11. Kanemoto K, Kawasaki J, Kawai I. Postictal psychosis: a comparison with acute interictal and chronic psychoses. Epilepsia 1996;37(6):551-6.
12. Devinsky O, Abrahmson H, Alper K, et al. Postictal psychosis: a case control study of 20 patients and 150 controls. Epilepsy Res 1995;20:247-53.
13. Umbricht D, Degreef G, Barr WB, Lieberman JA, Pollack S, Schaul N. Postictal and chronic psychoses in patients with temporal lobe epilepsy. Am J Psychiatry 1995;152(2):224-31.
14. Mendez MF, Grau R, Doss RC, Taylor TL. Schizophrenia in epilepsy: seizure and psychosis variables. Neurology 1993;43(6):1073-7.
15. Slater E, Beard AW. The schizophrenia-like psychoses of epilepsy. Br J Psychiatry 1963;109:95-150.
16. Marsh L, Rao V. Psychiatric complications in patients with epilepsy: a review. Epilepsy Res 2002;49:11-33.
17. Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 2002;43(Suppl 2):S19-S24.
18. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393-414.
19. Torta R, Monaco F. Atypical antipsychotics and serotonergic antidepressants in patients with epilepsy: pharmacodynamic considerations Epilepsia 2002;43(Supl. 2):S8-S13.
20. Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967;17(9):869-77.
21. Trimble MR. Long-term treatment of dysfunctional behavior in epilepsy. Baillière's Clin Psychiatry 1995;1:667-82.
22. Hensiek AE, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry 2002;72:281-5.
23. Blumer D, Wakhlu S, Montouris G, et al. Treatment of the interictal psychosis. J Clin Psychiatry 2000;61:110-22.
24. th Meeting of APA: New Research Program & Abstracts. Washington (DC): APA; 1996.
25. Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999;53(Suppl 2):S68-S75.
26. Fernandez HH, Friedman JH. Atypical neuroleptics in movement disorders. CNS Drugs 1999;11:467-83.
27. Long PW. Internet Mental Health (www.mentalhealth.com) Olanzapine drug monograph (from file Lilly) and Zotepine drug monograph. October; 1996.
28. Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 2000;47(11):1000-4.
29. Barnes TRE, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998;13(Suppl 3):S49-S57.
30. Owens MJ, Risch SC. Atypical antipsychotic. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmachology. Washington (DC): Am Psychiatric Press; 1995. p. 263-80.
31. Trimble MR. On the use of tranquillisers in epilepsy. Epilepsia 2002;43(Suppl. 2):S25-S27.
32. Monaco F, Cicolin A. Interations between anticonvulsivant and psychoactive drugs. Epilepsia 1999;40(Suppl 10):S71-S76.
33. Spina E, Perucca E. Clinical significance of pharmacokinetic interations between antiepileptic and psychotropic drugs. Epilepsia 2002;43(Suppl 2):S37-S44.
34. Spina E, Scordo MG, Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol 2001;21(1):108-9.
35. Forrest FM, Forrest IS, Serra MT. Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biol Psychiatry 1970;2(1):53-8.
36. Linnoila M, Viukari M, Vaisanen K, Auvinen J. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980;137(7):819-21.
37. Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998;20(6):628-30.
38. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21(1):89-93.
39. Facciola G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, Spina E. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999;21(3):341-5.
40. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36(7):487-8.